Отправить эту статью по почте 
СУЛЬБУТИАМИН В ПСИХИАТРИИ, НАРКОЛОГИИ, НЕВРОЛОГИИ И ОБЩЕСОМАТИЧЕСКОЙ МЕДИЦИНЕ (ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
Цель исследования: представить читателю данные о фармакологической активности сульбутиамина (одного из липофильных производных тиамина), о механизмах его терапевтического эффекта, о его показаниях к применению и о доказательной базе для его применения в психиатрии, наркологии и неврологии, а также при некоторых общесоматических патологиях.
Методология проведения работы: мы провели поиск и изучение литературных данных о тиамине и сульбутиамине в поисковых системах и базах данных PubMed, Google Scholar, Science Direct, с использованием соответствующих ключевых слов.
Результаты: найденные нами в ходе составления настоящего обзора литературные данные свидетельствуют о том, что сульбутиамин может обладать рядом ценных для клинической практики свойств, в частности, антиоксидантным, нейропротективным, ноотропным, психостимулирующим, энергизирующим и антиастеническим действием и, возможно, также умеренными антидепрессивными, анксиолитическими и анальгетическими свойствами. Он может быть эффективным в составе комплексной терапии деменции Альцгеймера, депрессивных и тревожных расстройств, расстройств аутистического спектра, синдрома дефицита внимания и гиперактивности, астенических состояний разного генеза и др.
Область применения результатов: результаты этого обзора заслуживают самого широкого применения в психиатрии, наркологии и неврологии.
Ключевые слова
Полный текст:
>PDF
Литература
Inouye K., Katsura E. “Etiology and pathology of beriberi.” In: Shimazono N, Katsura E, editors. Beriberi and Thiamine Igaku Shoin Ltd, 1965, pp. 1–28.
Lonsdale D. Thiamine tetrahydrofurfuryl disulfide: a little known therapeutic agent. Med Sci Monit, 2004, vol. 9, no. 10, pp. RA199-203.
Matsukawa T., Yurugi S., Matsuoka T. Products of the reaction between thiamine and ingredients of the plants of Allium genus: detection of allithiamine and its homologs. Science, 1953, vol. 3064, no.118, pp. 325–327. doi: 10.1126/science.118.3064.325
Lilly V.G., Barnett H.L., Anderson B.G. The effects of allithiamine on some thiamine-requiring organisms. Science, 1953, vol. 3071, no. 118, pp. 548–549. doi: 10.1126/science.118.3071.548
Asahi Y. Polarographic determination of ascorbic acid, riboflavin, pteroylglutamic acid, 2-methyl-1,4-naphthohydroquinone diacetate, thiamine, niacinamide and thiamine propyl disulfide in multivitamin preparations. J Vitaminol (Kyoto), 1958, vol. 2, no. 4, pp. 118–125. doi: 10.5925/jnsv1954.4.118
Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med, 2006, vol. 1, no. 3, pp. 49-59. doi: 10.1093/ecam/nek009
Murakami S., Arakawa T., Nakagawa M. Therapeutic effect of O-butyryl-thiamine disulfide (BuTDS) on cardiac function under general anesthesia – with reference to improvement of ECG findings. Nihon Geka Hokan, 1966, vol. 5, no. 35, pp. 879–904.
Tanaka H., Mizoguchi M., Fujimoto Y., Ishibe T. Clinical use of BuTDS in urological field. Hinyokika Kiyo, 1966, vol. 8, no. 12, pp. 811–822.
Gotoh K., Shinoda T., Kimura Y., Isogai K., Nishi M. Clinical experience with BuTDS in urological field. Hinyokika Kiyo, 1966, vol. 7, no. 12, pp. 709–712.
Tsuchida M., Kimura Y. Effects of BuTDS on postoperative intestinal paralysis. Hinyokika Kiyo, 1966, vol. 8, no. 12, pp. 808–810.
Fujihira E., Tarumoto Y., Ajioka M., Mori T., Nakazawa M. Analgesic effect of o-isobutyryl-thiamine disulfide on experimentally induced pain. Yakugaku Zasshi, 1973, vol. 3, no. 93, pp. 388–391.
Balestreri R., Bertolini S., Barban G. Effect of bis-(isobutyryloxy-2-ethyl)-1-N-(amino-4-methyl-2-pyrimidyl-5) methyl formamido-2-propene-1-yl disulfide (Sulbutiamin) in neurasthenic and neuroastheniform syndromes. Arch Maragliano Patol Clin, 1979, no. 35, pp. 19–34.
Morozov P.V. Novoe v lechenii astenii [News in therapy of asthenia]. Psychiatry and psychopharmacotherapy, 2005, no. 3, pp. 154–159.
Bettendorff L., Weekers L., Wins P., Schoffeniels E. Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues. Biochem Pharmacol, 1990, vol. 11. no. 40, pp. 2557–2560. doi: 10.1016/0006-2952(90)90099-7
Gusev S.I., Trifonov O.I., Snigireva G.Y. Primenenie eneriona dlya lecheniya astenicheskih sostoyanij v period dlitel’nyh remissij opijnoj narkomanii u osuzhdennyh podrostkov [The use of enerion fot the therapy of asthenic states in opioid use disorder in remission in criminal adolescents]. Voprosy narkologii, 2005, no. 6, pp. 21–28.
Bettendorff L. The compartmentation of phosphorylated thiamine derivatives in cultured neuroblastoma cells. Biochim Biophys Acta, 1994, vol. 1, no. 1222, pp. 7-14. doi: 10.1016/0167-4889(94)90019-1
Volvert M.L., Seyen S., Piette M., Evrard B., Gangolf M., Plumier J.C., Bettendorff L. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol, 2008, no. 8, pp. 10. doi: 10.1186/1471-2210-8-10
Novikova L.Y. Astenija – problema sovremennosti [Asthenia – a modern problem]. Ural’skij meditsinskij zhurnal, 2004, no. 1, pp. 22-26.
Micheau J., Durkin T.P., Destrade C., Rolland Y., Jaffard R. Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav, 1985, vol. 2, no. 23, pp. 195–198. doi: 10.1016/0091-3057(85)90555-6
Parada-Turska J., Turski W.A. Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology, 1990, vol. 12, no. 29, pp. 1111–1116. doi: 10.1016/0028-3908(90)90034-o
Staubli U., Rogers G., Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA, 1994, vol. 2, no. 91, pp. 777–781. doi: 10.1073/pnas.91.2.777
Puma C., Baudoin C., Bizot J.C. Effects of intraseptal infusions of N-methyl-D-aspartate receptor ligands on memory in an object recognition task in rats. Neurosci Lett, 1998, vol. 2, no. 244, pp. 97–100. doi: 10.1016/s0304-3940(98)00137-2
Pussinen R., Sirviö J. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol, 1999, vol. 2, no. 13, pp. 171–179. doi: 10.1177/026988119901300210
Levin E.D., Bettegowda C., Weaver T., Christopher N.C. Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial arm maze. Pharmacol Biochem Behav, 1998, vol. 3, no. 61, pp. 335–340. doi: 10.1016/s0091-3057(98)00109-9
Floresco S.B., Phillips A.G. Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav Neurosci, 2001, vol. 4, no. 115, pp. 934–939.
Bettendorff L., Hennuy B., De Clerck A., Wins P. Chloride permeability of rat brain membrane vesicles correlates with thiamine triphosphate content. Brain Res, 1994, vol. 1, no. 652, pp. 1571–60. doi: 10.1016/0006-8993(94)90331-x
Majid A.S., Yin Z.Q., Ji D. Sulphur antioxidants inhibit oxidative stress induced retinal ganglion cell death by scavenging reactive oxygen species but influence nuclear factor (erythroid-derived 2)-like 2 signalling pathway differently. Biol Pharm Bull, 2013, vol. 7, no. 36, pp. 1095–1110. doi: 10.1248/bpb.b13-00023
Kwag J., Majid A.S., Kang K.D. Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons. Biol Pharm Bull, 2011, vol. 11, no. 34, pp. 1759–1764. doi: 10.1248/bpb.34.1759
Kang K.D., Majid A.S., Kim K.A., Kang K., Ahn H.R., Nho C.W., Junge S.H. Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells. Neurochem Res, 2010, vol. 11, no. 35, pp. 1828–1839. doi: 10.1007/s11064-010-0249-5
Stahl S.M. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Ed. Cambridge University Press, 2013. ISBN 978-1107686465
Balzamo E., Vuillon-Cacciuttolo G. Facilitation of a state of wakefulness by semi-chronic treatment with sulbutiamin (Arcalion) in Macaca mulatta. Rev Electroencephalogr Neurophysiol Clin, 1982, vol. 4, no. 12, pp. 373–378. doi: 10.1016/s0370-4475(82)80029-4
Pan X., Gong N., Zhao J., Yu Z., Gu F., Chen J., Sun X., Zhao L., Yu M., Xu Z. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain, 2010, vol. 5, no. 133, pp. 1342-1351. doi: 10.1093/brain/awq069
Yang J., Li J.F., Zhao L. The Relationship Between GSK-3 and Mental Disorders. Sheng Li Ke Xue Jin Zhan, 2015, vol. 4, no. 46, pp. 250–254.
Alda M. Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry, 2015, vol. 6, no. 20, pp. 661–670. doi: 10.1038/mp.2015.4
Kao C.Y., Hsu Y.C., Liu J.W., Lee D.C., Chung Y.F., Chiu I.M. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. J Neurochem, 2013, vol. 1, no. 126, pp. 4–18. doi: 10.1111/jnc.12292
Sümegi A. Quetiapine in bipolar disorders. Neuropsychopharmacol Hung, 2008, vol. 5, no. 10, pp. 281–291.
Aubry J.M., Schwald M., Ballmann E., Karege F. Early effects of mood stabilizers on the Akt/GSK-3beta signaling pathway and on cell survival and proliferation. Psychopharmacology (Berl), 2009, vol. 3. no. 205, pp. 419–429. doi: 10.1007/s00213-009-1551-2
Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol, 2009, no. 49, pp. 327–347. doi: 10.1146/annurev.pharmtox.011008.145634
Douzenis A., Michopoulos I., Lykouras L. Sulbutiamine, an ‘innocent’ over the counter drug, interferes with therapeutic outcome of bipolar disorder. World J Biol Psychiatry, 2006, vol. 3, no. 7, pp. 183-185. doi: 10.1080/15622970500492616.
Lôo H., Poirier M.F., Ollat H., Elatki S. Effects of sulbutiamine (Arcalion 200) on psycho-behavioral inhibition in major depressive episodes. Encephale, 2000, vol. 2, no. 26, pp. 70–75.
McCormick L.M., Buchanan J.R., Onwuameze O.E., Pierson R.K., Paradiso S. Beyond alcoholism: Wernicke-Korsakoff syndrome in patients with psychiatric disorders. Cogn Behav Neurol, 2011, vol. 4, no. 24, pp. 209–216. doi: 10.1097/WNN.0b013e31823f90c4
Bizot J.C., Herpin A., Pothion S., Pirot S., Trovero F., Ollat H. Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task. Prog Neuropsychopharmacol Biol Psychiatry, 2005, vol. 29, no. 6, pp. 928–935. doi: 10.1016/j.pnpbp.2005.04.035
Harrison R.A., Vu T., Hunter A.J. Wernicke’s encephalopathy in a patient with schizophrenia. J Gen Intern Med, 2006, vol. 12. no. 21, pp. 8–11. doi: 10.1111/j.1525-1497.2006.00600.x
Sacks W., Esser A.H, Feitel B., Abbott K. Acetazolamide and thiamine: an ancillary therapy for chronic mental illness. Psychiatry Res, 1989, vol. 3, no. 28, pp. 279–288. doi: 10.1016/0165-1781(89)90208-4
Obrenovich M.E., Shamberger R.J., Lonsdale D. Altered heavy metals and transketolase found in autistic spectrum disorder. Biol Trace Elem Res, 2011, vol. 1-3, no. 144, pp. 475–486. doi: 10.1007/s12011-011-9146-2
Lonsdale D., Shamberger R.J., Obrenovich M.E. Dysautonomia in autism spectrum disorder: case reports of a family with review of the literature. Autism Res Treat, 2011, no 2011, pp. 129795. doi: 10.1155/2011/129795
Watanabe S., Yamakura S., Hirano K., Okumura Y., Aiba H. Case of infantile autism with pediatric Wernicke’s encephalopathy due to severe eating disorder. No To Hattatsu, 2009, vol. 1, no. 41, pp. 43–46.
Lonsdale D., Shamberger R.J., Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett, 2002, vol. 4, no. 23, pp. 303–308.
Simon N. Infantile autism and Wernicke’s encephalopathy. Med Hypotheses, 1990, vol. 3, no. 32, pp. 169–172. doi: 10.1016/0306-9877(90)90119-y
Hills J.I., Golub M.S., Bettendorff L., Keen C.L. The effect of thiamin tetrahydrofurfuryl disulfide on behavior of juvenile DBA/2J mice. Neurotoxicol Teratol, 2012, vol. 2, no. 34, pp. 242–252. doi: 10.1016/j.ntt.2011.07.006.
Brenner A. The effects of megadoses of selected B complex vitamins on children with hyperkinesis: controlled studies with long-term follow-up. J Learn Disabil, 1982, vol. 5, no. 15, pp. 258–264. doi: 10.1177/002221948201500501
Vichnar M. Experience with the administration of group B vitamins in children with the hyperkinetic syndrome. Cesk Psychiatr, 1988, vol. 4, no. 84, pp. 237–244.
Tikal K. Discussion of the article by M. Vichnar: Experience with the administration of group B vitamins to children with hyperkinetic syndrome. Cesk Psychiatr, 1989, vol. 3, no. 85, pp. 204–206.
Ollat H., Laurent B., Bakchine S., Michel B.F., Touchon J., Dubois B. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease. Encephale, 2007, vol. 2, no. 33, pp. 211–215. doi: 10.1016/s0013-7006(07)91552-3
Mimori Y., Katsuoka H., Nakamura S. Thiamine therapy in Alzheimer’s disease. Metab Brain Dis, 1996, vol. 11, no. 1, pp. 89–94. doi: 10.1007/BF02080934
Pogosova G.V. Psikhoemotsional’nye rasstrojstva u bol’nyh serdechno-sodudistymi zabolevanijami: voprosy lechenija [Psychoemotional disorders in patients with cardiovascular disorders: implications for therapy]. Kardiovaskuljarnaja terapija i profilaktika, 2006, vol. 5, no. 2, pp. 94–99.
Lebedev M.A., Palatov S.Yu., Kovrov G.V. Ustalost’ i eje projavlenija [Tiredness and its manifestations]. Russkij medicinskij zhurnal, 2014, vol. 22, no. 4, pp. 282–286.
Khasanova D., Mukhutdinova E., Zhitkova Yu. Enerion (sulbutiamin) v lechenij postinsult’nogo astenicheskogo sindroma [Enerion (sulbuthiamine) in the treatment of poststroke asthenia]. Vrach, 2008, no. 7, pp. 66–69.
Golovina A.G. Enerion v terapii astenicheskih rasstroistv u podrostkov v ambulatornoj psikhiatricheskoj praktike [Enerion in the treatment of asthenic states in adolescents in ambulatory psychiatric practice]. Psikhiatrija, 2004, vol. 9, no. 3, pp. 43–49.
Mikhajlova N.M. Primenenie eneriona dlya lechenija astenicheskih rasstroistv v psikhogeriatricheskoj praktike [The use of enerion for the treatment of asthenic states in psycho-geriatric practice]. Psikhiatrija, 2004, vol. 9, no. 3, pp. 65–75.
Gurak S.V., Parfenov V.A. Astenija posle insul’ta i infarkta miokarda i ee lechenie enerionom [Post-stroke and post-infarction asthenia and its treatment with enerion]. Klinicheskaja gerontologija, 2005, vol. 11, no. 8, pp. 9–12.
Levin O.S., Slizkova Yu.B. Primenenie eneriona pri lechenii astenicheskih rasstroistv u bol’nyh, perenjosshih ljegkuju cherepno-mozgovuju travmu [The use of enerion in patients who have been suffered from mild brain trauma]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2007, no. 5, pp. 44–48.
Vein A.M., Fedotova A.V., Gordeev S.A. Enerion – effektivnoe i bezopasnoe sredstvo dlya lechenija astenii u bol’nyh s psikhovegetativnym sindromom [Enerion – an effective and safe drug for the treatment of asthenia in patients with a psycho-vegetative syndrome]. Russkij medicinskij zhurnal, 2004, vol. 12, no. 10, pp. 631–634.
Butrina L.V. Optimizatsija farmakoterapii astenicheskogo sindroma u bol’nyh s somaticheskoj patologiej [The problem of optimal pharmacotherapy of asthenic syndromes in patients with various medical disorders]. Candidate of medical sciences thesis, Volgograd, 2004.
Bozhkova E.D. Dinamika nervno-psikhicheskih rasstroistv v protcesse reabilitatsii patsientov v rannem vosstanovitel’nom periode insul’ta [The dynamics of mental and psychological disorders in patients in early rehabilitation phase after stroke]. Candidate of medical sciences thesis, Nizhny Novgorod, 2006.
Safronova N.S., Naidich S.I., Polevik I.V. Vlijanie fizicheskih nagruzok i priema eneriona na formirovanie nespetsificheskih adaptatsionnyh reaktsij organizma futbolistov [The effect of physical activity and the use of enerion on the non-specific adaptive reactions of football players]. Uchenye zapiski Tavricheskogo natsional’nogo universiteta imeni V.I. Vernadskogo. Serija “Biologija, khimija”, 2009, vol. 22, no. 4, pp. 152–157.
Smirnov A.A. Kliniko-eksperimental’noe obosnovanie optimizatsii vosstanovitel’noj terapii bol’nyh distsirkuljatornoj entsefalopatiej [A clinical and experimental grounding for the optimization of rehabilitation therapy in patients with circulatory encephalopathy]. Candidate of medical sciences thesis, Ivanovo, 2006.
Bukhanovskij A.O., Galkin K.Yu., Mirzaeva L.M., Bukhanovskaja O.A. Enerion (sul’butiamin) v lechenii funktsional’noj astenii [Enerion (sulbuthiamine) in the treatment of functional asthenic states]. Juzhno-rossijskij meditsinskij zhurnal, 2002, no. 5, pp. 26–29.
Bondarchuk E.Yu. Kliniko-immunologicheskie i terapevticheskie aspekty nevrastenii v zrelom vozraste [Clinical, immunological and therapeutic aspects of neurasthenia in adult life]. Candidate of medical sciences thesis, Chelyabinsk, 2004.
Litvinovich E.F., Langeman T.I., Litvinovich S.F. Primenenie sul’butiamina (eneriona) v kombinirovannom lechenii bol’nyh s simptomaticheskoj fokal’noj epilepsiej [The use of sulbuthiamine (enerion) in the combined treatment of patients with symptomatic focal epilepsy]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2006, no. 2, pp. 68–70.
Kiew K.K., Wan Mohamad W.B., Ridzuan A., Mafauzy M. Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics. Malays J Med Sci, 2002, vol. 1, no. 19, pp. 21–27.
Linjeva O.I. Enerion v kompleksnoj terapii bol’nyh s sindromom chronicheskoj tazovoj boli [Enerion in the combination therapy of patients with chronic pelvic pain syndrome]. Rossijskij vestnik akushera-ginekologa, 2006, no. 2, pp. 41–43.
Manzardo A.M., He J., Poje A., Penick E.C., Campbell J., Butler M.G. Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend, 2013, vol. 2. no. 133, pp. 562-570. doi: 10.1016/j.drugalcdep.2013.07.035
Donovan A., Perelman M. BNF recommendations for the treatment of Wernicke’s encephalopathy: lost in translation? Alcohol Alcohol, 2013, vol. 6, no. 48, pp. 743. doi: 10.1093/alcalc/agt145
Dmitriev D.G., Gamidov S.I., Permiakova O.V. Clinical efficacy of the drug enerion in the treatment of patients with psychogenic (functional) erectile dysfunction. Urologiia, 2005, vol. 1, pp. 32–35.
Sobolevsky T., Rodchenkov G. Sulbutiamine in sports. Drug Test Anal, 2010, vol. 11-12, no. 2, pp. 643–646. doi: 10.1002/dta.183
DOI: https://doi.org/10.12731/2658-6649-2020-12-2-41-72
Ссылки
- На текущий момент ссылки отсутствуют.
(c) 2020 Roman Alexandrovich Bekker, Yuriy Vitalievich Bykov
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
ISSN 2658-6649 (print)
ISSN 2658-6657 (online)